

## Special Issue

# Novel Insights in Acute Lymphoblastic and Myeloblastic Leukemia

### Message from the Guest Editor

Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are bone marrow and blood cancers with abnormal populations of lymphocytes and myeloblasts, respectively, although both can induce complications at the central nervous system level. ALL and AML are heterogenous diseases; genetic and epigenetic alterations in cell progenitors cause a dysregulation of multiple and diverse signal transduction pathways. Therefore, we are pleased to invite researchers to contribute to this Special Issue which intends to address the need to find more new drug-able targets than can reach the heterogeneity of leukemic patients. Manuscripts that accommodate omics technologies and their integration, which explore previously published datasets and/or bioinformatics and artificial intelligence strategies to find out common or alternative drug-able routes, are also of interest in this Issue. Provocative insights from past and current research to consider new drug-able features will be appreciated. In this Special Issue, original research articles, short communications, opinions, and reviews are welcome.

---

### Guest Editor

Dr. María Hernández Valladares  
Department of Physical Chemistry, University of Granada, Granada,  
Spain

---

### Deadline for manuscript submissions

closed (29 February 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/si/142288](https://mdpi.com/si/142288)

*Cancers*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)